These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1682 related articles for article (PubMed ID: 29290265)
1. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265 [TBL] [Abstract][Full Text] [Related]
2. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406 [TBL] [Abstract][Full Text] [Related]
3. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related]
5. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411 [TBL] [Abstract][Full Text] [Related]
6. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550 [TBL] [Abstract][Full Text] [Related]
7. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312 [TBL] [Abstract][Full Text] [Related]
9. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604 [TBL] [Abstract][Full Text] [Related]
10. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? Chmielewska I; Dudzińska M; Szczyrek M; Świrska J; Wojas-Krawczyk K; Zwolak A PLoS One; 2021; 16(9):e0257484. PubMed ID: 34587185 [TBL] [Abstract][Full Text] [Related]
11. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392 [TBL] [Abstract][Full Text] [Related]
12. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219 [TBL] [Abstract][Full Text] [Related]
13. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930 [TBL] [Abstract][Full Text] [Related]
14. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Owen DH; Wei L; Bertino EM; Edd T; Villalona-Calero MA; He K; Shields PG; Carbone DP; Otterson GA Clin Lung Cancer; 2018 Nov; 19(6):e893-e900. PubMed ID: 30197259 [TBL] [Abstract][Full Text] [Related]
15. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416 [TBL] [Abstract][Full Text] [Related]
16. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121 [TBL] [Abstract][Full Text] [Related]
17. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082 [TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533 [TBL] [Abstract][Full Text] [Related]
19. Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy. Ebi N; Inoue H; Igata F; Okuma R; Kinoshita E; Kawabata T; Tan I; Osaki Y; Ikeda T; Nakao A; Shundo Y; Hamada N; Fujita M Anticancer Res; 2024 Jul; 44(7):3087-3095. PubMed ID: 38925810 [TBL] [Abstract][Full Text] [Related]
20. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Naqash AR; Ricciuti B; Owen DH; Florou V; Toi Y; Cherry C; Hafiz M; De Giglio A; Muzaffar M; Patel SH; Sugawara S; Burkart J; Park W; Chiari R; Sugisaka J; Otterson GA; de Lima Lopes G; Walker PR Cancer Immunol Immunother; 2020 Jul; 69(7):1177-1187. PubMed ID: 32140762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]